Table 2.
GRADE evidence table.
| Certainty assessment | No of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Uric lowering therapies | Placebo | Relative (95% CI) | Absolute (95% CI) | ||
| Left ventricular ejection fraction | ||||||||||||
| 3 | Randomised trials | Not serious | Not serious | Not serious | Seriousa | None | 163 | 165 | – | MD 1.63 % higher (1.61 lower to 4.88 higher) |
⊕⊕⊕○ moderate | Important |
| B-type natriuretic peptide and N-terminal-pro-B-type natriuretic peptide | ||||||||||||
| 5 | Randomised trials | Not serious | Seriousb | Not serious | Not serious | None | 387 | 383 | – | SMD 0.3 SD lower (0.64 lower to 0.04 higher) |
⊕⊕⊕○ moderate | Important |
| Six-Minute Walk Test | ||||||||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 170 | 167 | – | MD 3.47 m lower (14.84 lower to 7.9 higher) |
⊕⊕⊕⊕ high | Critical |
| Cardiovascular death | ||||||||||||
| 2 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 13/331 (3.9%) | 11/327 (3.4%) |
RR 1.16 (0.41 to 3.23) |
5 more per 1,000 (from 20 fewer to 75 more) |
⊕⊕⊕⊕ high | Critical |
| All-cause mortality | ||||||||||||
| 2 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None | 18/331 (5.4%) | 13/327 (4.0%) |
RR 1.36 (0.68 to 2.73) |
14 more per 1,000 (from 13 fewer to 69 more) |
⊕⊕⊕⊕ high | Critical |
a
The numbers of studies and participants are relatively low.
b
The results of the two subgroups are inconsistent. RR: relative risk. m: meters.